Difficulty passing on costs amid inflation and yen depreciation under regulated prices
First written in FY2024-Q2. 6 of 7 entries say "Restated". Latest entry: FY2027-H1.
0 other companies' latest entry also says "Restated".
- FY2027-H1RestatedAnnual report
「Because each of the group's businesses is based primarily on regulated prices, the businesses are characterized by difficulty in passing cost increases on to prices.」
The company continues to recognize the risk that it is difficult to pass cost increases on to prices because the dispensing pharmacy, healthcare and pharmaceutical wholesaling businesses are based primarily on regulated prices. - 2026-07-10RestatedEarnings
「Because each of our Group's businesses is based primarily on administratively determined prices, the nature of these businesses makes it difficult to pass cost increases on to prices.」
The Group continues to recognise as a risk that businesses based primarily on administratively determined prices have difficulty passing cost increases on to prices. - FY2026RestatedAnnual report
「Because passing through higher costs resulting from rising prices is difficult, future revisions to drug price standards and dispensing fees, or changes to points and other rates, could affect the group's business performance.」
The company continues to identify as risks the difficulty of passing through higher costs when prices rise in businesses based primarily on administered prices, and the impact on performance of revisions to drug prices and dispensing fees. - 2026-04-06RestatedEarnings
「Going forward, attention will be required with respect to uncertainty surrounding the situation in the Middle East, the resulting surge in crude oil prices, and rising domestic prices, although」
The situation in the Middle East, surging crude oil prices and rising domestic prices are identified as factors requiring attention in the business environment. - FY2025RestatedAnnual report
「Because passing through higher costs resulting from rising prices is difficult, future revisions to drug price standards and dispensing fees, or changes to points and other rates, could affect the group's business performance.」
The company continues to identify as risks the difficulty of passing through higher costs when prices rise in businesses based primarily on administered prices, and the impact on performance of revisions to drug prices and dispensing fees. - FY2024-Q3RestatedAnnual report
「The current business environment is characterized by higher costs driven by rapid inflation and yen depreciation, which are pushing up prices. The group's 3 businesses, pharmaceutical dispensing, healthcare and pharmaceutical wholesaling, are all based primarily on administered prices. The rise in prices is likely to have a major adverse impact because passing through higher costs is difficult.」
The company continues to identify rising costs due to inflation and yen depreciation, and the difficulty of passing through these costs in its 3 businesses based primarily on administered prices, as major business risks. - FY2024-Q2First statedAnnual report
「The current business environment is characterized by rapidly accelerating inflation, while higher costs resulting from the yen's depreciation are also pushing up prices. The group's 3 businesses, pharmaceutical dispensing, healthcare and pharmaceutical wholesaling, are all based primarily on administered prices. The rise in prices is likely to have a major adverse impact because passing through higher costs is difficult.」
Because the 3 businesses, pharmaceutical dispensing, healthcare and pharmaceutical wholesaling, are based primarily on administered prices, it is difficult to pass through cost increases resulting from inflation and yen depreciation. The company has explicitly identified for the first time the risk that rising prices could have a major adverse impact on its businesses.